#USA #Los Gatos #Shifamed #Akura Medical #VTE Care

Akura Medical Secures $53 Million in Series C Financing

Akura Medical, an innovative company within the Shifamed portfolio, has recently announced the successful closing of a $53 million Series C financing round. This investment aims to propel the development of groundbreaking technologies in venous thromboembolism (VTE) care. Established to transform the landscape of VTE treatment, Akura Medical focuses on developing advanced solutions that prioritize patient outcomes and procedural precision.

The financing was primarily led by the Qatar Investment Authority (QIA) and includes support from existing investors. The capital will be directed towards several key initiatives, including the continued development of the Katana™ Thrombectomy System and NavIQ™ quantification software, as well as completing the enrollment phase of the QUADRA-PE clinical trial and pursuing crucial regulatory approvals.

In a statement, Amr Salahieh, Chair and Acting CEO of Akura Medical, highlighted the significance of this funding for the company’s growth trajectory. He noted, “Akura Medical is advancing a differentiated portfolio of venous thrombectomy technologies aimed at improving procedural precision and patient outcomes. The introduction of our NavIQ quantification software marks a significant advancement toward intelligent, data-driven thrombectomy.”

With the investment from QIA, Akura Medical plans to expedite product development and solidify its foundation for future growth, aligning perfectly with its vision of enhancing VTE care. This financing not only supports the company’s innovative projects but also highlights the confidence investors place in Akura’s vision and strategic direction.

Akura Medical’s Product Innovations

Akura Medical's commitment to advancing VTE care is exemplified in its leading products:

• - Katana™ Thrombectomy System: This sophisticated system is tailored for modern thrombectomy procedures. It is designed to efficiently remove various clot types using high-velocity saline jets that facilitate effective clot disruption while minimizing the risk of catheter clogs. By integrating real-time sensors for pulmonary artery pressure, the system enhances procedural oversight, enabling healthcare providers to make informed decisions during treatment.

• - NavIQ™ Quantification Software: This software is designed to convert CT angiograms into detailed 3D models of the pulmonary vasculature. These models allow physicians to visualize anatomy and clot formations, aiding in pre-procedural planning and delivering critical data on clot characteristics to better prioritize treatment plans.

VTE is a significant health concern, noted as the third leading cause of cardiovascular-related deaths in the United States. It primarily arises when a blood clot forms in deep veins, often in the legs, which can subsequently impair blood flow to the lungs, presenting considerable risks to patient health.

About Akura Medical

As a privately held entity under Shifamed LLC, Akura Medical is adept at addressing the complexities associated with VTE. The firm's flagship Katana Thrombectomy System is envisioned to redefine standards in pulmonary embolism treatment, making a lasting impact on patient care and safety. The company is committed to innovating healthcare solutions that meaningfully alter the patient experience.

For further information about Akura Medical and its transformative technologies, visit Akura Medical. Please note that the Katana System is currently for investigational use only and is not yet cleared for sale in the USA or other markets.

About Shifamed, LLC

Founded by serial entrepreneur Amr Salahieh, Shifamed is recognized as a medical innovation hub that specializes in accelerating the development of groundbreaking medical solutions. The organization focuses on reducing risks and increasing impact, ultimately driving the delivery of innovative healthcare that ensures patients live healthier, longer lives. Learn more about Shifamed at Shifamed.